Pro-inflammatory and pro-coagulant properties of 6-thioguanine and 6-mercaptopurine: Implications for their potential role in the development of sinusoidal obstruction syndrome

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 164-167

  Bruneau, Johanna C ^a   O'Marcaigh, Aengus ^b   Smith, Owen P ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MERCAPTOPURINE; PROCOAGULANT; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ENDOTHELIUM CELL; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LETTER; LIVER DISEASE; LIVER SINUSOID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SINUSOIDAL OBSTRUCTION SYNDROME;

6-MERCAPTOPURINE; CELL LINE, TUMOR; COAGULANTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; INFLAMMATION; JURKAT CELLS; LYMPHOMA, LARGE B-CELL, DIFFUSE; STEM CELL TRANSPLANTATION; THIOGUANINE; TREATMENT OUTCOME;

EID: 74949119757     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903370353     Document Type: Letter

References (14)

1. Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004;10:RA247-RA254.
2. Coppell J, Brown S, Perry D. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003;17:63-70.
3. Faioni EM, Mannucci PM. Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis. Leuk Lymphoma 1997;25:233-245.
4. de Boer NK, Reinisch W, Teml A, et al. Dutch 6-TG working group. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 2006;73:25-31.
5. Bearman SI. Avoiding hepatic veno-occlusive disease: what do we know and where are we going? Bone Marrow Transplant 2001;27:1113-1120.
6. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol 2000;12:103-109.
7. Cutler C, Aldridge J, Kim HT, et al. Prediction of VOD using biomarkers of endothelial injury. Blood 2008;112:Abstract 3267.
8. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-3020.
9. Gomez-Quiroz L, Bucio L, Souza C, et al. Interleukin 8 response and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde or lipopolysaccharide. Hepatol Res 2003;26:134-141.
10. Rowell DL, Eckmann L, Dwinell MB, et al. Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion. Am J Physiol Gastrointest Liver Physiol 1997;273:G322-G332.
11. Stork L, Sather H, Hutchinson R, et al. Comparison of mercaptopurine with thioguanine and IT methotrexate wit IT "triples" in children with standard risk (SR) ALL: results of CCG-1952. Blood 2002;100:36a.
12. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-1348.
13. Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related venoocclusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 2006;80:375-383.
14. Schedel J, Gödde A, Schütz E, et al. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Ann NY Acad Sci 2006;1069:477-491.